Vermillion said this week that it has signed a deal with Quest Diagnostics to make OVA1, its protein biomarker-based ovarian cancer diagnostic, available in India beginning in the second quarter of this year.
"India represents an outstanding market opportunity where there are approximately 350 million women," CEO Gail Page said in a statement.
During Vermillion's 2010 earnings call in February, Page highlighted the company's international ambitions, noting that it planned to launch OVA1 in either India, England, or Mexico by the middle of this year (GWDN 2/10/2011).
In 2010, the first year OVA1 was commercially available, Vermillion sold an estimated 6,155 tests, exceeding the company's adjusted 2010 guidance of 5,000 to 5,500 tests, while falling short of its initial 8,000 to 10,000 test guidance (PM 01/07/2011).
Quest operates a 65,000 square-foot facility in Gurgaon, in the National Capital Region of India, that offers more than 700 tests using technology and quality standards that comply with global best practices, Vermillion said.